Research Publications

New drugs for hepatitis C virus.

Pockros PJ

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies.

Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, Shapiro DA

Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis.

Goodman ZD, Becker RL Jr, Pockros PJ, Afdhal NH

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis.

Pockros PJ, Jeffers L, Afdhal N, Goodman ZD, Nelson D, Gish RG, Reddy KR, Reindollar R, Rodriguez-Torres M, Sullivan S, Blatt LM, Faris-Young S

How should hepatitis C be managed in patients aged 65 years and older?

Nourani S, Pockros PJ

Noninvasive markers of fibrosis in chronic hepatitis patients.

Pockros PJ

Impact of obesity on treatment of chronic hepatitis C.

Charlton MR, Pockros PJ, Harrison SA

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.

Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, Ferenci P, Ackrill AM, Willems B

Chronic hepatitis C in patients with persistently normal alanine transaminase levels.

Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, Rodríguez-Torres M, Lardelli P, Blotner S, Zeuzem S